MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval
PR98456
GENEVA, Oct. 25, 2022 /PRNewswire=KYODO JBN/ --
Following our communication last week "MedAlliance to be acquired by Cordis",
MedAlliance is pleased to make the following announcement:
Photo - https://mma.prnewswire.com/media/1928464/MedAlliance_Image.jpg
Logo - https://mma.prnewswire.com/media/1196864/MedAlliance_Logo.jpg
SELUTION SLR(TM), MedAlliance's novel sirolimus-eluting balloon, has received
FDA Investigational Device Exemption (IDE) approval to initiate its coronary
pivotal clinical trial. This is the first sustained limus release coronary
drug eluting balloon (DEB) to receive FDA IDE approval for In-stent Restenosis
(ISR) indication. The study has already begun enrollment in Europe.
"We are pleased with the speed of European enrollment and look forward to
enrolling the first US patient before the year end; US site selections are
underway and will be finalized over the next several weeks. This study has the
potential to address the important unmet need of a non-stent treatment for the
ongoing problem of in-stent restenosis," commented Dr Don Cutlip, Principal
Investigator of the IDE SELUTION4ISR Study and the Chief Medical Officer at,
Baim Institute for Clinical Research.
"This is another significant milestone for MedAlliance: we were the first
sustained limus release balloon to receive FDA IDE approval, the first to begin
enrollment and now the first to have three applications approved. This is the
culmination of a multi-year R&D program that delivered comprehensive
pre-clinical data meeting the very high standards of the US FDA," added Jeffrey
B. Jump, MedAlliance Chairman and CEO. "We are very pleased with the high
level of market acceptance we are experiencing in Europe, Asia and South
America, and we look forward to entering the US market following the successful
culmination of this important clinical study and receipt of FDA approval. We
are currently enrolling our US Below-the-knee (BTK) study, enrollment is ahead
of schedule.
"We have had significant success with enrollment of the larger randomized
sister study, the international coronary SELUTION DeNovo study, and are
excited to offer this new treatment option to US patients, avoiding permanent
metal implants. No drug coated balloon is currently approved in the US for
coronary indications."
MedAlliance was the first drug-eluting balloon company to receive FDA
Breakthrough Designation status. In addition to the BTK and superficial
femoral artery (SFA) indications for which the company received FDA IDE
approval in May and August 2022, MedAlliance has now received coronary in-stent
restenosis (ISR) IDE approval. In the next few weeks, MedAlliance plans to
submit its 4th IDE application, for de novo coronary artery lesions, which will
complement the substantial experience that the company has gained with the
SELUTION DeNovo trial in Europe. More than 540 patients of the 3,326 planned
have already been enrolled in this ground-breaking coronary randomized
controlled study comparing SELUTION SLR vs. any limus drug-eluting stent (DES).
The study is powered to demonstrate superiority of SELUTION SLR DEB over DES
for coronary de novo artery disease. This is the largest DEB study ever
initiated and has the potential to change medical practice where implants
(metal stents) have been the standard of care for more than 30 years.
Enrollment of the IDE SELUTION4ISR FDA coronary study is already ongoing in
Europe, and will start in the US later this year. The trial will be conducted
at up to 60 centers worldwide, and in up to 40 centers in the US. This study
is powered to demonstrate non-inferiority vs. standard of care, (80% against
DES and 20% against POBA), and is currently 10% enrolled (ClinicalTrials.gov
Identifier: NCT04280029).
SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral
artery disease in February 2020 and for the treatment of coronary artery
disease in May 2020.
MedAlliance's unique DEB technology involves MicroReservoirs which contain a
mixture of biodegradable polymer intermixed with the anti-restenotic drug
sirolimus applied as a coating on the surface of an angioplasty balloon. These
MicroReservoirs provide controlled and sustained release of the drug for up to
90 days(1).
SELUTION SLR is commercially available in Europe, Asia, the Middle East and
the Americas (outside USA) and most other countries where the CE Mark is
recognized and over 10,000 units have already been used for patient treatments
in routine clinical practice or as part of clinical trials.
Contact: Richard Kenyon, rkenyon@medalliance.com, +44 7831 569940
SOURCE MedAlliance
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。